ผู้เขียน: Kanokwan

HONG KONG, Sep 1, 2025 - (ACN Newswire via SeaPRwire.com) - Black Spade Capital Limited (“Black Spade”) recently held a private meeting with Ark Invest.Mr. Dennis Tam, President and CEO of Black Spade, met with Ms. Catherine Wood, CEO and CIO of Ark Invest, to discuss key trends in AI, robotics, blockchain applications, energy storage, and cellular sequencing. Ms. Wood expressed optimism about AI and robotics, noting these technologies will not just displace jobs but also create new opportunities. She highlighted the potential of blockchain and space exploration, emphasizing that the world is advancing toward a more innovative and interconnected future. Mr. Tam advised family offices to focus on digital assets, AI, and robotics-focused funds, stocks, and ETFs, as these sectors are set to drive global economic growth. He explained that industries integrating these innovations will see significant productivity gains, boosting competitiveness in a fast-paced market. He encouraged family offices to adjust their asset allocations based on risk tolerance and invest in these emerging fields to support development and pursue higher returns. Ms. Wood predicted strong growth in cryptocurrencies, forecasting Bitcoin could reach USD 1.5 million and Ethereum USD 166,000 around 2030. She expressed confidence in the long-term potential of digital assets. Mr. Tam added that digital assets are becoming a mainstream asset class, with growing adoption by banks and government institutions creating strong momentum. In summary, Black Spade Capital urges family offices to act swiftly by investing in funds, stocks, and ETFs linked to AI, robotics, and digital assets. These sectors will drive economic and technological development, improve efficiency in traditional industries, and offer significant returns, positioning investors at the forefront of the next technological revolution.Photo caption:From the left: Mr. Dennis Tam, President and CEO of Black Spade and Ms. Catherine Wood, CEO and CIO of Ark InvestAbout Black Spade Capital LimitedBlack Spade Capital Limited is an established family office that manages the private investments of Mr. Lawrence Ho. Headquartered in Hong Kong, its global portfolio consists of a wide spectrum of cross-border investments as it consistently seeks to add new projects and opportunities to its investment mix. Black Spade’s investment strategy maximizes coverage of geographic regions and sectors whilst maintaining a portfolio of diversified asset classes, ranging from equity, fixed income, medical technology, leisure and culture, green energy, real estate to Pre-IPO investments. In August 2023, Black Spade Acquisition Co, a blank check company (SPAC) sponsored by Black Spade, completed a US$23 billion business combination with VinFast Auto Ltd. In 2024, Black Spade listed its second SPAC, Black Spade Acquisition II Co, which completed a business combination with global media and entertainment powerhouse The Generation Essentials Group in about 9 months in June 2025.Media Enquiries:Strategic Financial Relations Limited     Vicky LeeTel: +852 2864 4834Email: vicky.lee@sprg.com.hkIris Au YeungTel: +852 2114 4913Email: iris.auyeung@sprg.com.hkWebsite: www.sprg.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHANGHAI, Sep 1, 2025 - (ACN Newswire via SeaPRwire.com) - 28th August, The 2025 19th Frost & Sullivan Global Growth, Innovation and Leadership Summit and the 4th New Investment Event, hosted by Frost & Sullivan and co-organized by LeadLeo, was successfully held at the Jing'an Shangri-La Hotel in Shanghai from August 27 to 28, 2025. With the theme of "Intelligence Initiates a New Journey·Jointly Shaping Global Growth Engines", the Summit consists of an opening ceremony, eight parallel forums and a series of thematic activities, gathering over 200 heavyweight guests from home and abroad, more than 100 speeches/roundtable discussions, and attracting over 4,000 professional attendees.Frost & Sullivan has a history of nearly 30 years hosting Growth, Innovation and Leadership Summits worldwide, and this marks the 19th consecutive year of hosting the Summit in China. The 2025 Frost & Sullivan 19th GIL Summit featured in-depth discussions on hot topics such as AI and digital economy, new investments in life sciences, new consumption trends, ESG and new quality productive forces, high-quality development of listed companies, intelligent manufacturing going global and the global development of Chinese enterprises, jointly exploring new growth drivers, new markets and new tracks for China's economy in the new era. Focusing on cutting-edge industrial trends and capital movements, the Summit covers areas including macroeconomics, technological innovation, healthcare, energy storage, artificial intelligence and ESG practices, and released nearly 20 significant research findings on-site.Mr. David Frigstad, Global Chairman of Frost & Sullivan, highlighted the importance of the “Transformational Growth Journey,” which Frost & Sullivan defines as a seven-stage process to help companies navigate disruption and achieve sustainable success. He explained that the journey begins with understanding industry ecosystems across nine value chains, then leveraging data through the Growth Generator to enable rapid decision-making. Mr. David Frigstad emphasized that CEOs must view the world through a lens of prioritized growth opportunities and benchmark their organizations against global best practices. He also pointed to the Frost Radar as a tool for measuring future growth potential, built on both execution and innovation. Finally, Mr. David Frigstad underlined the role of community and collaboration, noting that true transformation requires openness to partnerships, new ideas, and global perspectives.Mr. Aroop Zutshi, Global President and Managing Partner of Frost & Sullivan, centered his speech on "Empowering Enterprises' Transformational Growth Journey", delivering an in-depth sharing focusing on global economic changes and corporate development, illuminating the growth path for enterprises seeking breakthroughs. He pointed out that the global economy is currently experiencing an unprecedented wave of change, and most enterprises are trapped in transformation dilemmas. The root causes lie in the difficulty in responding to change, missing hidden strategic opportunities and lacking a clear transformation framework. Only by taking proactive actions and focusing on strategic priorities can enterprises gain a firm foothold in the market reshuffle. To address the transformation challenges of enterprises, Mr. Aroop Zutshi proposed the "Top 5 Strategic Imperatives", including: 1. Transformation; 2. Ecosystem; 3. Growth Generator; 4. Growth Opportunities; 5. Frost Radar, Best Practices and Companies to Action, forming a systematic solution to support enterprises' transformational growth.Mr. Aroop Zutshi also detailed the six phases of Frost & Sullivan's "Growth Pipeline Engine", from growth audit and opportunity screening to strategy implementation and dynamic optimization, forming a interlocking systematic growth process to ensure that corporate growth is implementable and sustainable. Facing the Intelligence Revolution that began in 2023, he emphasized that this round of revolution is different from the Agricultural Revolution and the Industrial Revolution. By leveraging intelligent AI architectures, enterprises can deeply integrate deep web data, internal enterprise data and real-time public information. Only by equipping themselves with adaptive systems can enterprises seize technological dividends and occupy competitive high grounds. This sharing not only pointed out a way for enterprises to break through from "survival" to "development", but also conveyed clear growth value: by unifying team goals, stimulating innovation vitality and transforming strategies into practical actions, enterprises can not only avoid the risks of change, but also enhance their future growth potential, achieve sustainable high-quality development in the era of the Intelligence Revolution, and inject strong momentum into industrial transformation.Dr. Neil Wang, Global Partner and Greater China Chairman of Frost & Sullivan, stated that the theme of the Frost & Sullivan Summit has always centered on growth, innovation and leadership, adding value to enterprises, empowering industries and contributing to the national socio-economic development. He pointed out that the long-term, sustained and steady growth of China's economy is one of the greatest positives for the world. Frost & Sullivan not only studies the current growth of China's economy, but also focuses on predicting the future. At this Summit, Frost & Sullivan once again updated and released the White Paper on China's Industrial Development Trends in the Next 50 Years (4th Edition), hoping to help enterprises better grasp market opportunities and cope with challenges. According to his introduction, since entering China nearly 30 years ago, Frost & Sullivan has not only served a large number of innovative technology enterprises, but also actively engaged in technological innovation, such as proposing the concept of "AI + HI" (Artificial Intelligence + Human Intelligence) to empower the transformation and upgrading of traditional industries. Dr. Neil Wang believes that the core competitiveness of an enterprise lies in the leadership of entrepreneurs. The mission of Frost & Sullivan China is to convey China's growth, innovation, and leadership to the world, enabling the world to more clearly understand China's value and helping China accelerate its embrace of global opportunities.About Frost & SullivanFrost & Sullivan, the Transformational Growth company, enables clients to accelerate their growth and achieve best-in-class positions in growth, innovation, and leadership. The company’s Growth Pipeline as a Service provides the CEO’s Growth Team with transformational strategies and best-practice models to drive the generation, evaluation, and implementation of powerful growth opportunities. Let us be your growth coach on this transformational journey, as we actively support you in fostering collaborative initiatives within your industry’s ecosystem.About Frost & Sullivan GIL SummitThe Growth, Innovation and Leadership Summit founded by Frost & Sullivan has a history of nearly 30 years and is held in more than 20 countries and regions around the world. It has attracted in-depth participation from a large number of Global 1000 companies, top domestic and foreign financial institutions and other leading enterprises, helping them identify opportunities, continuously innovate, accelerate growth and gain a leading position in an increasingly complex and changing world. Since its launch in China in 2008, the Frost & Sullivan GIL Summit has been held for the 19th time. It has become an important platform for outstanding domestic enterprises, the investment community and regulatory authorities to exchange successful experiences and jointly explore development directions, as well as a key window for the world to understand China's cutting-edge development trends.Media ContactFrost & SullivanShanghai, ChinaRachel ZhangE: rachel.zhang@frostchina.comT: +86 021-3209-6800W: http://www.frostchina.com/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Sep 1, 2025 - (ACN Newswire via SeaPRwire.com) - On August 29, Everest Medicines (1952.HK) announced its interim results for the six months ended June 30, 2025. The Company’s total revenue for the first half of 2025 reached RMB 446 million, representing 48% year-over-year growth, while operating expenses as a percentage of revenue decreased by 40.1 percentage points, reflecting strong operational efficiency. Non-IFRS loss narrowed by 31%, and gross margin excluding non-cash items was 76.4%. As of the end of June, the Company maintained a solid cash balance of RMB 1.6 billion. Additionally, with the successful completion of a share placement on August 1, which generated net proceeds of HK$1.553 billion, Everest’s total cash position increased further, providing a strong foundation for commercialization expansion and R&D investment. Supported by the excellent performance of its core products, Everest remains confident in achieving its full-year revenue guidance of RMB 1.6 to 1.8 billion and expects to turn operating cash flow positive in Q4.BOCOM International released its latest report today, noting that the strong sales performance of Everest Medicines’ Nefecon(R) far exceeded expectations. The institution significantly raised its revenue forecasts for 2026–2027 and lifted its target price to HK$84. The report highlighted a rich pipeline of catalysts from the second half of 2025 through 2026, including the approval, commercialization, and reimbursement negotiations of etrasimod in China, as well as potential BD opportunities for the Company’s proprietary pipeline. BOCOM International believes the current valuation remains attractive and reiterated its “Buy” rating.“In the first half of 2025, Everest Medicines accelerated its transformation into a leading global biopharmaceutical company by deepening our ‘dual-engine’ strategy. We have built a commercialization platform anchored by two blockbusters covering high-potential markets and powered by the in-house discovery and clinical translation of in vivo CAR-T and mRNA therapeutic cancer vaccine platforms.” said Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines.Core Products Deliver Strong Growth, Driving Commercial Platform MomentumNEFECON(R), the blockbuster product in the renal portfolio, delivered particularly strong performance. As the first and only fully approved etiological treatment for IgA nephropathy (IgAN) in China, the United States, and Europe, NEFECON(R) generated revenue of RMB 303 million in the first half of 2025, representing 81% year-over-year growth. However, our first half revenue was artificially low due to a supply constraint that was rooted in both strong market demand and a delay in regulatory approval of a supplemental application for production scale up designed to ensure supply stability. This has been fully resolved since our supplemental application was approved by the China CDE on Aug 1, 2025. Following the supplemental application was approved by the China CDE in August, supply capacity increased significantly. Cumulative sales from January to August reached RMB 825 million, including RMB 520 million in August alone, reflecting strong market demand. Full-year sales are expected to reach RMB 1.2–1.4 billion, with continued strong growth projected in 2026, potentially reaching RMB 2.4–2.6 billion.Another Core product XERAVA(R), As the world’s first fluorocycline antibiotic recorded RMB 143 million in the first half of 2025, up 6% year-over-year. In-hospital sales increased 37% year-over-year, driven by Everest’s core hospital strategy.Additionally, VELSIPITY(R) (etrasimod), a best-in-disease therapy for moderately to severely active ulcerative colitis (UC), is positioned as Everest’s next growth engine, with its NDA in mainland China expected to be approved in the first half of 2026. The localized production project for VELSIPITY(R) was officially launched at the Jiashan manufacturing site in March 2025, providing strong support for its future commercialization.Global Proprietary Pipeline Value Emerging，Strong Prospects for Blockbuster Potential Everest continues to focus on achieving key breakthroughs in its proprietary pipeline, while accelerating the clinical development and global expansion of innovative assets with global rights. EVER001 (civorebrutinib), the next-generation covalent reversible BTK inhibitor, has delivered encouraging Phase 1b/2a clinical data in primary membranous nephropathy (pMN). With potential applications in IgAN, minimal change disease (MCD), and FSGS, covering a patient population of more than 10 million worldwide, EVER001 represents a significant market opportunity, with projected global peak sales exceeding RMB 10 billion. A global Phase II basket trial is expected to be initiated in the first half of 2026.Leveraging its industry-leading mRNA therapeutic cancer vaccine platform and in vivo CAR-T platform, the Company is building a globally competitive R&D pipeline. EVM18, the in vivo CAR-T program, has completed multiple non-human primate (NHP) trials and achieved preclinical proof-of-concept, with first-in-human data expected by the end of 2025. EVM16, the personalized therapeutic mRNA cancer vaccine, has initiated its first-in-human trial in China, with patient dosing completed. In the investigator-initiated trial (IIT), dose escalation in the low- and mid-dose cohorts has been completed, with encouraging preliminary data observed. EVM14, an off-the-shelf tumor-associated antigen (TAA) vaccine, has received IND approval from the U.S. FDA and acceptance from China’s NMPA. The Phase I trial in the U.S. is currently underway, with first patient enrollment expected by September 2025. EVM15, the immune-modulatory cancer vaccine, has completed preclinical proof-of-concept and identified its clinical candidate.Strategic Repositioning to Bolster Global CompetitivenessDuring the reporting period, the Hong Kong Stock Exchange approved the removal of the “B” marker from Everest’s stock short name, reflecting recognition of the Company’s strong R&D pipeline, commercialization capabilities, and overall business fundamentals. In addition to the successful top-up placement, Everest invested approximately US$30.9 million in I-Mab (Nasdaq: IMAB) in August 2025. Following the transaction, Everest increased its ownership in I-Mab to approximately 16.1%, becoming its single largest shareholder, further strengthening its global presence in next-generation immuno-oncology therapies.Analysts noted that Everest’s “dual-engine” strategy is rapidly delivering results. On the one hand, the Company’s powerful commercial platform—anchored by NEFECON(R) and VELSIPITY(R) and supported by XERAVA(R), Cefepime-taniborbactam, EVER001, and other high-potential assets—is expected to generate synergies with total peak sales exceeding RMB 25 billion globally. On the other hand, Everest’s in vivo CAR-T and mRNA therapeutic cancer vaccine platforms provide significant long-term growth potential through global development and partnership opportunities. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

NEW YORK, Sept 1, 2025 - (ACN Newswire via SeaPRwire.com) - me88 news, a dedicated sports journalism platform, announced its official launch today, designed to provide comprehensive coverage and expert analysis across four key competitive disciplines: Formula 1, E-sports, Badminton, and Martial Arts.Addressing the Information Gap in Sports MediaThe launch of me88 news responds to the growing demand for specialized sports content that goes beyond surface-level reporting. Unlike traditional sports platforms that prioritize click-driven headlines, me88 news focuses on delivering substantive analysis, technical breakdowns, and exclusive behind-the-scenes content that enhances readers' understanding of competitive sports."The sports media landscape is saturated with recycled content and sensational headlines," said Owen Parker at me88 news. "Our platform represents a commitment to journalism that respects both the intelligence of our audience and the complexity of modern competitive sports."Comprehensive Multi-Sport Coverageme88 news provides specialized reporting across four distinct sporting categories:Formula 1: Technical analysis covering paddock politics, pit lane strategies, and the engineering innovations that define modern motorsportE-sports: Tournament coverage, player profiles, and analysis of the rapidly evolving digital athletics landscapeBadminton: In-depth coverage of one of the world's most physically demanding racket sports, featuring tactical analysis and athlete profilesMartial Arts: Comprehensive reporting spanning traditional disciplines to modern competitive fighting, honoring both heritage and contemporary innovationReal-Time Global CoverageThe platform operates with around-the-clock reporting capabilities, ensuring readers receive timely updates regardless of global time zones. Features include live event coverage, instant post-competition analysis, and multimedia content including highlight reels and exclusive interviews.Beyond breaking news, me88 news offers editorial content designed to foster informed discussion within the sports community, including opinion pieces, feature stories, and long-form investigations into the human stories behind athletic achievement.Industry Positioning and Future Outlookme88 news enters a competitive digital sports media market with a differentiated approach focused on quality over quantity. The platform's launch reflects broader industry trends toward specialized content and expert analysis as audiences increasingly seek authoritative sources for sports information.The company plans to expand coverage areas and enhance multimedia offerings as the platform develops its audience base and establishes its position within the sports media ecosystem.About me88 newsme88 news is a sports journalism platform dedicated to providing comprehensive coverage and analysis across multiple competitive disciplines. Through strategic partnerships and expert-driven content, me88 news serves sports enthusiasts seeking in-depth analysis that enhances their understanding and appreciation of competitive athletics.Media ContactCompany: me88 newsContact: Media TeamWebsite: https://me88news.com/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com